Rising consumption of anticoagulants in Central and Eastern European countries in the period 2007-2019

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F24%3A10492656" target="_blank" >RIV/00216208:11160/24:10492656 - isvavai.cz</a>

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NBnWCbl3mq" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NBnWCbl3mq</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.36290/csf.2024.036" target="_blank" >10.36290/csf.2024.036</a>

Result language

angličtina

Original language name

Rising consumption of anticoagulants in Central and Eastern European countries in the period 2007-2019

Original language description

Introduction and Aim: Due to the growing incidence of thromboembolic disease and atrial fibrillation, increasing trends in anticoagulants consumption can be expected. The aim of this study was to analyse the consumption of anticoagulants in the Czech Republic, Croatia, Hungary, Romania, and Slovakia between 2007 and 2019. Methods: A retrospective analysis of anticoagulants comprising B01AA, B01AB, B01AE, B01AF and B01AX was performed using ATC/DDD methodology. The analysis was initiated in the year before the launch of the first non-vitamin K oral anticoagulant (NOAC). The consumption of each drug was assessed based on annual data and was expressed as DDD per 1,000 population per day (DDD/TID). Results: The overall rates of anticoagulant consumption increased in all countries. Specifically, doubled in the Czech Republic, Croatia, and Slovakia, more than tripled in Hungary and more than quadrupled in Romania. Parenteral anticoagulant consumption remained stable or decreased, while the proportion of oral anticoagulants increased from an average of 61.41% in 2009 to 66.95% in 2019. The use of vitamin K antagonists declined, with the highest rate in the Czech Republic (11.16 DDD/TID in 2019). NOAC consumption showed substantial growth: from 0.002 to 8.33 DDD/TID in the Czech Republic, 0.001 to 6.73 in Croatia, 0.009 to 8.31 in Hungary, 0.0005 to 5.40 in Romania, and 0.03 to 10.77 in Slovakia. By 2019, rivaroxaban was the most commonly used NOAC in all countries, apart from Romania. Conclusion: The study showed an overall increase in the anticoagulant consumption. However, specific characteristics of individual countries need to be further analysed to better understand the different factors influencing utilization patterns.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Česká a slovenská farmacie

ISSN

1210-7816

e-ISSN

1805-4439

Volume of the periodical

73

Issue of the periodical within the volume

4

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

"E1"-"E8"

UT code for WoS article

—

EID of the result in the Scopus database

999